Posted by Michael Wonder on 19 Aug 2022
Aeglea BioTherapeutics announces European Medicines Agency validation of marketing authorisation application for pegzilarginase for the treatment of arginase 1 deficiency
18 August 2022 - Aeglea BioTherapeutics today announced that a marketing authorisation application for pegzilarginase for the treatment of arginase 1 deficiency has been submitted to and successfully validated by the EMA.
The marketing authorisation application was submitted by Immedica Pharma, Aeglea's commercialisation partner in Europe and the Middle East.
